A61K 31/4523
Containing further heterocyclic ring systems
Official title: containing further heterocyclic ring systems
A61K31/4523 (Containing further heterocyclic ring systems) appears on 6,086 US grants and 11,330 published applications in this corpus.
Search patents in A61K- Granted patents
- 6,086
- Published applications
- 11,330
- Assignees
- 3,320
- Inventors
- 22,163
- Latest grant
- 6 Oct 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1976 | 1 | 0 |
| 1977 | 1 | 0 |
| 1978 | 0 | 0 |
| 1979 | 0 | 0 |
| 1980 | 0 | 0 |
| 1981 | 0 | 0 |
| 1982 | 0 | 0 |
| 1983 | 0 | 0 |
| 1984 | 0 | 0 |
| 1985 | 0 | 0 |
| 1986 | 0 | 0 |
| 1987 | 0 | 0 |
| 1988 | 0 | 0 |
| 1989 | 0 | 0 |
| 1990 | 1 | 0 |
| 1991 | 0 | 0 |
| 1992 | 1 | 0 |
| 1993 | 5 | 0 |
| 1994 | 3 | 0 |
| 1995 | 22 | 0 |
| 1996 | 48 | 0 |
| 1997 | 58 | 0 |
| 1998 | 86 | 0 |
| 1999 | 83 | 0 |
| 2000 | 79 | 0 |
| 2001 | 94 | 49 |
| 2002 | 103 | 150 |
| 2003 | 96 | 168 |
| 2004 | 55 | 190 |
| 2005 | 57 | 207 |
| 2006 | 60 | 167 |
| 2007 | 49 | 201 |
| 2008 | 69 | 225 |
| 2009 | 70 | 239 |
| 2010 | 98 | 275 |
| 2011 | 111 | 273 |
| 2012 | 152 | 277 |
| 2013 | 221 | 445 |
| 2014 | 289 | 529 |
| 2015 | 366 | 605 |
| 2016 | 363 | 606 |
| 2017 | 445 | 645 |
| 2018 | 438 | 602 |
| 2019 | 423 | 613 |
| 2020 | 407 | 661 |
| 2021 | 366 | 614 |
| 2022 | 297 | 648 |
| 2023 | 249 | 623 |
| 2024 | 309 | 765 |
| 2025 | 289 | 856 |
| 2026 | 222 | 697 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Subgroups
Granted patents
- A61K 31/454Containing a five-membered ring with nitrogen as a ring hetero atom2,989
- A61K 31/4545Containing a six-membered ring with nitrogen as a ring hetero atom2,601
- A61K 31/4535Containing a heterocyclic ring having sulfur as a ring hetero atom630
- A61K 31/4525Containing a five-membered ring with oxygen as a ring hetero atom483
- A61K 31/453Containing a six-membered ring with oxygen as a ring hetero atom289
Recent patents
- Oral liquid formulation of apixaban6 Oct 2026US 12,751,947 B2Liqmeds Worldwide Limited
- CCR6 receptor modulators6 Oct 2026US 12,753,168 B2Idorsia Pharmaceuticals Ltd
- Combination therapies of FASN inhibitors with thyroid hormone receptor agonists29 Sep 2026US 12,746,242 B2Sagimet Biosciences Inc.
- LOX enzyme inhibiting methods and compositions29 Sep 2026US 12,746,243 B2Anovia Biosciences, Inc.
- TEAD inhibitors29 Sep 2026US 12,747,207 B2Orion Corporation
- Pharmaceutical oral dosage form of q2038 Oct 2026US 2026/0306411 A1Qurient Co., Ltd.
- Composition for removing and inhibiting senescent cells, and uses thereof8 Oct 2026US 2026/0306460 A1Lifeceutix Co., Ltd.
- Tomm6-interacting extracts and compounds for use in the treatment and prophylaxis of nervous system diseases, atherosclerosis, hepatitis b infection and human papilloma virus (hpv) infection8 Oct 2026US 2026/0306473 A1
- Inhaled statins as bronchodilators to improve lung function in respiratory diseases8 Oct 2026US 2026/0306477 A1Beth Israel Deaconess Medical Center, Inc.
- Methods of treating diseases and disorders associated with foxp3 expression8 Oct 2026US 2026/0306482 A1Northwestern University
Most cited
By later US patents
- Methods for treating multiple myeloma with 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione after stem cell transplantation733US 9,101,621 B2Celgene Corporation · 2015
- Method of moving a delivery member of a dispensing device for administration of oral transmucosal dosage forms654US 8,499,966 B2AcelRx Pharmaceuticals, Inc. · 2013
- Methods and compositions for inhibition of angiogenesis231US 5,712,291 AChildren's Medical Center Corporation · 1998
- Methods and compositions for inhibition of angiogenesis185US 5,629,327 AChildren's Hospital Medical Center · 1997
- Pharmaceutical composition containing acid addition salt of basic drug163US 6,255,502 B1Farmarc Nederland BV · 2001